Skip to main content
Premium Trial:

Request an Annual Quote

Gentris Licenses LGC s CYP450 Polymorphism for Use in Genotyping Service

NEW YORK, June 7 (GenomeWeb News) - Gentris has taken a non-exclusive license from LGC for a common drug-metabolism polymorphism, the companies said today.


According to the terms of the agreement, Gentris gains the rights to make, use, and sell diagnostic products and services that rely on LGC's CYP450 2D6*4 polymorphism.


Gentris plans to use the polymorphism in its genotyping service, CEO Michael Murphy said.


LGC is the exclusive licensor of the polymorphism.


The *4 polymorphism is the most common CYP450 2D6 polymorphism in Caucasians, and the 2D6 gene itself is believed to be involved in the metabolism of about 30 percent of approved drugs.

The Scan

Nature Papers Examine Genomes of Centenarians, Transcription-Coupled DNA Repair

In Nature this week: analysis of centenarian genomes uncovers longevity-linked variants, and more.

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.